Ongoing Clinical Trials for Testicular Germ Cell Tumour
Currently, there is 1 ongoing clinical trial for patients with testicular germ cell tumour. This trial is being conducted in France and focuses on preventing blood clots in patients undergoing chemotherapy with cisplatin.
Clinical trial locations
Study on Preventing Blood Clots in Patients with Advanced Germ Cell Tumors Using Cisplatin and a Drug Combination
This clinical trial is designed for patients with advanced germ cell tumors who are beginning their first round of chemotherapy. The main goal is to test whether a preventive treatment called thromboprophylaxis can effectively prevent dangerous blood clots, known as venous thromboembolic events, during chemotherapy.
Who can participate:
- Male patients aged 18 years or older
- Those diagnosed with good or intermediate prognosis germ cell tumor according to specific medical classification
- Patients who have not received any previous cancer treatment with chemotherapy
- Those suitable for first-line chemotherapy with cisplatin
- Patients who have at least one risk factor for blood clots, such as elevated LDH enzyme levels, body surface area greater than 1.9, or large lymph nodes in the abdomen measuring more than 5 cm
- Must be able to sign informed consent and attend regular study visits
- Must be affiliated with a social security system
Who cannot participate:
- Female patients
- Patients who belong to vulnerable populations requiring special protection
What the study involves:
The trial evaluates the effectiveness of medications designed to prevent blood clots in patients receiving cisplatin-based chemotherapy. Participants will receive one of several blood clot prevention medications, including tinzaparin sodium (INNOHEP), dalteparin sodium (Fragmin), or enoxaparin sodium (LOVENOX). These are given as injections under the skin. Some patients may receive a placebo, which contains no active medication, to help researchers compare the effects.
The study follows a structured approach: after signing consent and undergoing initial health assessments, patients begin chemotherapy with cisplatin while simultaneously receiving the blood clot prevention treatment. Throughout the treatment period, which lasts up to 13 weeks, patients are closely monitored for any signs of blood clots or side effects. Regular follow-up visits continue for up to six weeks after the last chemotherapy cycle to watch for any delayed complications.
Investigational drugs:
The main chemotherapy drug used in this trial is cisplatin, a platinum-based medication that works by damaging the DNA of cancer cells, preventing them from dividing and ultimately causing them to die. It is administered through a vein and is a well-established treatment for various cancers, including advanced germ cell tumors. The blood clot prevention medications (tinzaparin, dalteparin, and enoxaparin) work by thinning the blood to reduce the risk of dangerous clots forming during chemotherapy.
Summary
At present, there is one active clinical trial available for patients with testicular germ cell tumour, located in France. This study specifically addresses an important complication of chemotherapy treatment: the risk of blood clots. Patients with certain risk factors who are beginning cisplatin-based chemotherapy may be eligible to participate. The trial focuses on evaluating different blood-thinning medications to determine which approach best prevents blood clots while patients undergo cancer treatment. This research aims to improve the safety and outcomes for patients receiving chemotherapy for advanced germ cell tumors.